Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


BRAF And Related Inhibitors In Development

This article was originally published in Pharmaceutical Approvals Monthly

You may also be interested in...

New Research Highlights Potential And Pitfalls Of BRAF Inhibitors

Surprisingly positive data from two early-stage trials in metastatic melanoma with Plexxikon/Roche’s BRAF inhibitor, PLX-4032, and its quick move into Phase III, is garnering attention for the new class of cancer therapy. But there is one troubling sign of toxicity, and other research on the BRAF pathway is prompting debate over the pros and cons of specific versus broad activity.

FDA Priority Review Voucher Redemption Fee Set At $4.6 Million In FY 2011

Redeeming a priority review voucher obtained by developing a drug for a tropical disease will cost companies $6.1 million in fiscal 2011

September 2010 Approvals






Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts